Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“All my 2026 current myeloma algorithms in one thread. From smoldering to newly diagnosed to relapsed. Bookmark!
1) Smoldering Myeloma
Main message: I recommend Daratumumab X 3 years for high-risk smoldering myeloma.
2) Newly Diagnosed Myeloma
Main message: Quadruplets are standard of care for most patients. The quads I recommend are DaraVRd or IsaVRd
3) Treatment of First Relapse
Main Message: The unprecedented results with Tec-Dara have changed the paradigm and approach.
4) Treatment of Second Relapse
Main message: For BCMA-sensitive, the approach is similar to the first relapse. For the second relapse, belantamab combinations provide an additional option.
5) Treatment of refractory myeloma
Main message: There are many options. But we need more. Good news is more are coming.
6) Summary of the most currently available active drugs.
Black font are approved ones.
7) mSMART risk stratification of myeloma
8) Details on the Tec Dara trial that changed the algorithms in relapse a lot!”
More posts featuring Vincent Rajkumar.